A Study of Viracept in HIV-Positive Women
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002171
- Lead Sponsor
- Agouron Pharmaceuticals
- Brief Summary
The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count \<= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Baylor Univ
🇺🇸Houston, Texas, United States
HIV Outpatient Clinics / LA State Univ Med Ctr
🇺🇸New Orleans, Louisiana, United States
Univ of Southern California / LA County USC Med Cntr
🇺🇸Los Angeles, California, United States